LEADER 02151nam  2200361   450 
001 9910683366003321
005 20230703095537.0
010   $a3-0365-6897-2
035   $a(CKB)5700000000354572
035   $a(NjHacI)995700000000354572
035   $a(EXLCZ)995700000000354572
100   $a20230703d2023      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aModel-Informed Precision Dosing /$fedited by Jona?s Samuel Pe?rez-Blanco, Jose? Marti?nez Lanao
210  1$aBasel :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2023.
215   $a1 online resource (320 pages)
311   $a3-0365-6896-4 
330   $aModel-informed precision dosing (MIPD) is an advanced quantitative approach focusing on individualized treatment optimization. MIPD integrates mathematical models of drugs and diseases combined with individual patient characteristics (e.g., genotype, anthropometric factors, and organ function). MIPD has been highlighted as a useful tool for drug dosage selection in both the drug development process and clinical practice and it is a rapidly growing discipline that is supported by the main drug regulatory agencies. Despite the potential benefits of this methodology toward personalized medicine, its application is still limited. The Special Issue presented here includes several PKPD and PBPK models focused on improving the current state of art regarding the PK behaviour of different drugs with the aim of improving the efficacy/safety balance of these treatments and their clinical outcome; the Special Issue is intended to be of particular interest for clinical pharmacologists, pharmacometricians, and specific clinicians who routinely use the considered drugs.
606   $aDrugs$xDosage
615  0$aDrugs$xDosage.
676   $a615.14
702   $aPe?rez-Blanco$b Jona?s Samuel
702   $aLanao$b Jose? Marti?nez
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910683366003321
996   $aModel-Informed Precision Dosing$93086503
997   $aUNINA